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   Nine patients with persistent urinary incontinence due to neurogenic bladder and intolerable 
systemic side effects on oral anticholinergic agents were treated with intravesical instillation of 
oxybutynin hydrochloride. Two tablets  (6  mg) dissolved in 10 ml of physiological saline or sterile 
water were instilled into the bladder two times daily via self intermittent catheterization. The 
mean bladder capacity increased from 128 to 212 ml 1 month after intravesical instillation of oxy-
butynin hydrochloride, although this difference was not significant. The bladder was augmented 
more efficaciously in patients with overactive detrusor than patients with an underactive detrusor. 
Subjective improvement was recognized in 4 patients. Among 5 patients who discontinued therapy 
due to ineffective results, maximum urethral closure pressure below 50  cmHzO was seen in 4. In-
travesical instillation of oxybutynin hydrochloride was considered to be ineffective clinically in 
patients with underactive detrusor and low urethral closure pressure. Although no systemic side 
effects were observed, a decrease of bladder capacity was recognized in 2 patients. 
                                                (Acta Urol. Jpn. 41:  521-524,1995)





































量と定義 した.2)自覚所見;注 入開始1ヵ 月後に,
尿失禁に関する患者の印象をもとにその有効性を検討




























































































































(排尿時低活動型)を 示す症例で は平均13%であ っ
た.膀胱コソプライアンスに関しても有意の増加はみ
られなかった.自覚所見上尿失禁がほとんど認められ
なくなった改善例は2例 であ り,また尿失禁の軽減 し
たやや改善例も2例認められた.最大膀胱容量が30%
以上増加したのは4症例であ り,自覚所見上やや改善
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